Medeiros, Gustavo C. http://orcid.org/0000-0002-0091-1192
Gould, Todd D.
Prueitt, William L.
Nanavati, Julie
Grunebaum, Michael F. http://orcid.org/0000-0001-5940-3478
Farber, Nuri B. http://orcid.org/0000-0003-3178-1877
Singh, Balwinder http://orcid.org/0000-0001-7062-8192
Selvaraj, Sudhakar http://orcid.org/0000-0002-9494-172X
Machado-Vieira, Rodrigo
Achtyes, Eric D. http://orcid.org/0000-0001-8939-1535
Parikh, Sagar V.
Frye, Mark A. http://orcid.org/0000-0001-6997-4215
Zarate, Carlos A. Jr
Goes, Fernando S. http://orcid.org/0000-0001-6262-8264
Article History
Received: 17 November 2021
Revised: 17 May 2022
Accepted: 31 May 2022
First Online: 27 June 2022
Competing interests
: TDG is listed as co-author on patent and patent applications related to the pharmacology and use of (<i>2</i> <i>R,6</i> <i>R</i>)<i>-hydroxynorketamine</i> in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorder. He has assigned his patent rights to the University of Maryland Baltimore, but will share a percentage of any royalties that may be received. TDG has received research funding from Allergan and Roche Pharmaceuticals, and has served as a consultant for FSV7 LLC, during the preceding 3 years. NBF holds patents pertaining to improved use of NMDA antagonists as therapeutic agents. EDA has served on advisory boards for Alkermes, Janssen, Lundbeck/Otsuka, Roche, Sunovion and Teva and reports previous stock holdings in AstraZeneca, Johnson & Johnson, Moderna, and Pfizer. EDA has received research support from Alkermes, Astellas, Biogen, Boehringer-Ingelheim, InnateVR, Janssen, National Network of Depression Centers, Neurocrine Biosciences, Novartis, Otsuka, Pear Therapeutics, Takeda and serves on the SMI Adviser LAI Center of Excellence (unpaid). BS reports research time support from Medibio (unrelated to the current study); grant support from Mayo Clinic. SS has received grants/research support from NIMH R21 (1R21MH119441 – 01A1) and SAMHSA (FG000470-01) and research supplement funds from The University of Texas Health Science Center at Houston. SS has received speaking honoraria from British Medical Journal Publishing Group and received research support from Compass pathways, Janssen and LivaNova. RMV has received consulting fees from Eurofarma Pharmaceuticals. Abbott and BioStrategies group, and has a research contract for trials with Janssen and Boehringer-Ingelheim Pharmaceuticals. RMV has also received speaker fees from Otsuka, Lundbeck, EMS, and Cristalia and is a member of the scientific board of Symbinas Pharmaceuticals and Allergan. SVP has received honoraria for consulting or research funds from Assurex (Myriad), Sage, Otsuka, Takeda, Janssen, Aifred, Mensante, Canadian Institutes for Health Research, Ontario Brain Institute, and the Flinn Foundation. MAF has received Grant Support from Assurex Health, and Mayo Foundation. He also has financial interests in Chymia LLC. CAZ is a full-time U.S government employee. He is listed as a coinventor on a patent for the use of ketamine in major depression and suicidal ideation. CAZ is listed as a coinventor on a patent for the use of (2 R,6 R)-hydroxynorketamine, (S)-dehydronorketamine, and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine metabolites in the treatment of depression and neuropathic pain. CAZ is listed as co-inventor on a patent application for the use of (2 R,6 R)-hydroxynorketamine and (2 S,6 S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. CAZ has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. FSG has received research grant support from Janssen Therapeutics. GCM, WLP, JN, and MFG do not have conflicts of interest to report.